Full-Time

Senior Scientist / Principal Scientist

Process Chemistry

Treeline Biosciences

Treeline Biosciences

51-200 employees

Biotech firm discovering cancer therapies.

Compensation Overview

$166.4k - $189.5k/yr

San Diego, CA, USA

In Person

On-site in San Diego; travel up to 10% to manufacturing plants and partner sites.

Category
Biology & Biotech (2)
,
Requirements
  • Ph.D. in Organic Chemistry or related discipline with 3–8+ years of relevant industry or postdoctoral experience; M.S. with 6–10+ years of industry experience also considered.
  • Strong expertise in synthetic organic chemistry, reaction development, and route design.
  • Experience with complex molecule synthesis and route optimization.
  • Familiarity with scale-up considerations and impurity control in chemical processes.
  • Ability to work effectively within cross-functional discovery teams.
  • Experience working with and managing external CDMO partners.
  • Strong written and verbal communication skills.
  • Strong project leadership skills with the ability to manage complex timelines, multiple stakeholders, and evolving program priorities.
  • Strong communication and collaboration skills with a proven ability to work cross-functionally in a fast-paced, science-driven environment.
  • High level of personal integrity, commitment to excellence and to our patients
Responsibilities
  • Collaborate with medicinal chemistry partners to support candidate selection and developability assessments. Advise and assist with sourcing scaffolds and intermediates as appropriate.
  • Design and execute route scouting and synthetic strategies for drug candidates and key intermediates.
  • Design and optimize chemical transformations and scalable synthetic routes to enable efficient and robust processes for discovery and early development programs.
  • Enable rapid compound synthesis and methodologies to support SAR campaigns and discovery timelines.
  • Apply modern synthetic technologies to address complex synthetic challenges.
  • Support multi-gram to kilogram-scale synthesis for biological and toxicology studies.
  • Manage external partners and cultivate strong, collaborative relationships to support program objectives.
  • Contribute to early CMC understanding, including impurity identification and process considerations.
  • Communicate results through technical reports, documentation, and presentations.
  • May be involved with preparations for the first GMP synthesis of a clincial candidate for Phase 1 trials.
  • Ability to travel up to 10% to support program needs, including on-site support at manufacturing plants and partner collaboration.
Desired Qualifications
  • Experience with modern synthetic methodologies and technologies (e.g., catalysis, flow chemistry, photochemistry, high-throughput experimentation, as well as other techniques).
  • Experience enabling synthesis of structurally complex drug candidates or emerging modalities.
  • Demonstrated creative problem solving in synthetic chemistry.

Treeline Biosciences develops proprietary therapies for cancer and other serious diseases by conducting in-depth R&D across biology, chemistry, protein sciences, and computational science. Its product work involves discovering and optimizing drug candidates, then licensing these therapies to larger pharmaceutical companies or selling them to healthcare providers, with support from CRO collaborations to speed development. The company differentiates itself through a balanced mix of in-house research and external partnerships, a robust IP strategy, and a team that blends experienced biotech veterans with new talent, all backed by funding from KKR to scale operations. Its goal is to build a sustainable, long-term pipeline of treatments that can reach patients while expanding capabilities and partnerships in the biotech ecosystem.

Company Size

51-200

Company Stage

Series A

Total Funding

$1.1B

Headquarters

Stamford, Connecticut

Founded

2021

Your Connections

People at Treeline Biosciences who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Three Phase 1 assets create multiple 2026 clinical catalysts.
  • $1.1 billion funding supports execution without near-term financing pressure.
  • Expansion into neurology and autoimmune diseases broadens the platform beyond oncology.

What critics are saying

  • All disclosed programs remain early-stage, leaving valuation exposed to weak readouts.
  • Reverse-merger execution can distract management and delay public-market access.
  • KRAS and lymphoma programs face intense competition from better-capitalized rivals.

What makes Treeline Biosciences unique

  • Josh Bilenker and Jeffrey Engelman combine oncology and R&D leadership.
  • Treeline integrates in-house chemistry, biology, protein science, and computation.
  • Its pipeline spans small molecules, degraders, glues, and targeted ADCs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Hybrid Work Options

Wellness Program

Mental Health Support

Phone/Internet Stipend

Home Office Stipend

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Childcare Support

Elder Care Support

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

-2%
Endpoints News
Sep 3rd, 2025
Josh Bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B

Josh bilenker's Treeline Biosciences gets another $200M, bringing funding to $1.1B.

Business Wire
Sep 3rd, 2025
Treeline Biosciences Secures $200M, Starts Trials

Treeline Biosciences announced the start of Phase 1 trials for three programs: TLN-121 (BCL6 degrader) and TLN-254 (EZH2 inhibitor) for lymphoma, and TLN-372 (pan-KRAS inhibitor) for KRAS-mutated cancers. They also secured a $200 million Series A extension, totaling $1.1 billion in funding. CEO Josh Bilenker highlighted their aim to create a leading biopharma company with innovative cancer treatments.

VentureCapital.com
Sep 3rd, 2025
Treeline Biosciences Commences Phase 1 Trials and Secures $200 Million Series A Extension Funding

Treeline Biosciences commences Phase 1 trials and secures $200 million Series A extension funding.

VC News Daily
Jan 5th, 2025
Treeline Biosciences Raises $421M Funding

Treeline Biosciences, a drug discovery startup based in Watertown, MA, has secured $421 million in October's largest fundraising round.

The Business Journals
Dec 30th, 2024
Treeline Biosciences raises $421.8M in 2024

Treeline Biosciences, based in Watertown, raised the largest venture capital round by a Massachusetts biotech in 2024, securing $422 million. Co-founded by Joshua Bilenker and Jeffrey Engelman, the company focuses on challenging molecular targets in oncology.